Date Abhijit A, Hanes Justin, Ensign Laura M
The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA.
The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Departments of Biomedical Engineering, Environmental and Health Sciences, Oncology, Neurosurgery, Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD 21205, USA.
J Control Release. 2016 Oct 28;240:504-526. doi: 10.1016/j.jconrel.2016.06.016. Epub 2016 Jun 9.
The oral route is a preferred method of drug administration, though achieving effective drug delivery and minimizing off-target side effects is often challenging. Formulation into nanoparticles can improve drug stability in the harsh gastrointestinal (GI) tract environment, providing opportunities for targeting specific sites in the GI tract, increasing drug solubility and bioavailability, and providing sustained release in the GI tract. However, the unique and diverse physiology throughout the GI tract, including wide variation in pH, mucus that varies in thickness and structure, numerous cell types, and various physiological functions are both a barrier to effective delivery and an opportunity for nanoparticle design. Here, nanoparticle design aspects to improve delivery to particular sites in the GI tract are discussed. We then review new methods for evaluating oral nanoparticle formulations, including a short commentary on data interpretation and translation. Finally, the state-of-the-art in preclinical targeted nanoparticle design is reviewed.
口服途径是一种首选的药物给药方法,不过实现有效的药物递送并将脱靶副作用降至最低往往具有挑战性。将药物制成纳米颗粒可以提高其在恶劣的胃肠道环境中的稳定性,为靶向胃肠道特定部位、增加药物溶解度和生物利用度以及在胃肠道中实现持续释放提供机会。然而,胃肠道独特且多样的生理学特性,包括pH值的广泛变化、厚度和结构各异的黏液、众多细胞类型以及各种生理功能,既是有效递送的障碍,也是纳米颗粒设计的契机。在此,我们讨论了改善纳米颗粒向胃肠道特定部位递送的设计方面。接着,我们回顾了评估口服纳米颗粒制剂的新方法,包括对数据解读和转化的简短评论。最后,我们综述了临床前靶向纳米颗粒设计的最新进展。